BACITRACIN ZINC; POLYMYXIN B SULFATE - Generic Drug Details

What are the generic sources for bacitracin zinc; polymyxin b sulfate and what is the scope of freedom to operate?

Bacitracin zinc; polymyxin b sulfate is the generic ingredient in four branded drugs marketed by Glaxosmithkline, Bausch And Lomb, Padagis Us, Sciegen Pharms, Pharmafair, Monarch Pharms, and Naska, and is included in seven NDAs. Additional information is available in the individual branded drug profile pages.

Three suppliers are listed for this compound.

Summary for BACITRACIN ZINC; POLYMYXIN B SULFATE

US Patents:	0
Tradenames:	4
Applicants:	7
NDAs:	7
Finished Product Suppliers / Packagers:	3
Clinical Trials:	1
DailyMed Link:	BACITRACIN ZINC; POLYMYXIN B SULFATE at DailyMed

Recent Clinical Trials for BACITRACIN ZINC; POLYMYXIN B SULFATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Glaxo Wellcome	N/A
National Institute of Allergy and Infectious Diseases (NIAID)	N/A

See all BACITRACIN ZINC; POLYMYXIN B SULFATE clinical trials

Pharmacology for BACITRACIN ZINC; POLYMYXIN B SULFATE

Drug Class	Polymyxin-class Antibacterial
Physiological Effect	Decreased Cell Wall Synthesis & Repair

Anatomical Therapeutic Chemical (ATC) Classes for BACITRACIN ZINC; POLYMYXIN B SULFATE

A07AA	Antibiotics
A07A	INTESTINAL ANTIINFECTIVES
A07	ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
A	Alimentary tract and metabolism

D06AX	Other antibiotics for topical use
D06A	ANTIBIOTICS FOR TOPICAL USE
D06	ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE
D	Dermatologicals

J01XB	Polymyxins
J01X	OTHER ANTIBACTERIALS
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

J01XX	Other antibacterials
J01X	OTHER ANTIBACTERIALS
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

R02AB	Antibiotics
R02A	THROAT PREPARATIONS
R02	THROAT PREPARATIONS
R	Respiratory system

S01AA	Antibiotics
S01A	ANTIINFECTIVES
S01	OPHTHALMOLOGICALS
S	Sensory organs

S01AA	Antibiotics
S01A	ANTIINFECTIVES
S01	OPHTHALMOLOGICALS
S	Sensory organs

S02AA	Antiinfectives
S02A	ANTIINFECTIVES
S02	OTOLOGICALS
S	Sensory organs

S03AA	Antiinfectives
S03A	ANTIINFECTIVES
S03	OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS
S	Sensory organs

US Patents and Regulatory Information for BACITRACIN ZINC; POLYMYXIN B SULFATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline	POLYSPORIN	bacitracin zinc; polymyxin b sulfate	AEROSOL;TOPICAL	050167-002	Mar 1, 1985		DISCN	No	No
Sciegen Pharms	BACITRACIN ZINC AND POLYMYXIN B SULFATE	bacitracin zinc; polymyxin b sulfate	OINTMENT;OPHTHALMIC	064028-001	Jan 30, 1995		DISCN	No	No
Monarch Pharms	POLYSPORIN	bacitracin zinc; polymyxin b sulfate	OINTMENT;OPHTHALMIC	061229-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Pharmafair	OCUMYCIN	bacitracin zinc; polymyxin b sulfate	OINTMENT;OPHTHALMIC	062430-001	Apr 8, 1983		DISCN	No	No

Market Dynamics and Financial Trajectory for Bacitracin Zinc and Polymyxin B Sulfate

Last updated: February 19, 2026

What are the current market sizes and trends for bacitracin zinc and polymyxin B sulfate?

Bacitracin zinc and polymyxin B sulfate are antibiotics primarily used in topical formulations to treat skin infections, burns, and for wound management. The combined market for these agents is influenced by rising antibiotic resistance, regulatory changes, and the growth of topical antimicrobial products.

Market Valuation (2022):

• The global topical antibiotic market, including bacitracin zinc and polymyxin B sulfate, was valued at approximately USD 1.2 billion.
• Expected compound annual growth rate (CAGR): 4.3% (2023–2030) (Grand View Research, 2023).

Market Drivers:

• Increasing prevalence of skin infections and wound care needs.
• Growing urbanization and healthcare infrastructure investments.
• Regulatory approvals of generic formulations expanding access.
• Rising antibiotic resistance, prompting demand for combination topical therapies.

Market Challenges:

• Stringent patent cliff for branded products.
• Concerns about antibiotic resistance and regulations limiting over-the-counter access.
• Competition from alternative topical antimicrobials and natural products.

How do formulations and regulatory environments influence market growth?

Most formulations of bacitracin zinc and polymyxin B sulfate are topical ointments and creams. The formulations are often combined with other antimicrobials, impacting their market share.

Regulatory Landscape:

• In the US, the FDA regulates combination topical antibiotics as monograph or NDA products.
• Generic formulations dominate the market, leading to price competition.
• Some countries tighten regulations on over-the-counter antibiotics to curb resistance.

Implication for revenue:

• Market growth is higher in regions where regulations facilitate OTC sale.
• In markets with strict prescription requirements, growth depends on new formulations and indications.

How is patent and exclusivity affecting revenues?

• Breadth of patent protections for specific formulations or delivery systems has declined.
• Most formulations now rely on generic manufacturers, exerting downward pressure on prices.
• No recent patent litigations or exclusivities are reported for core active ingredients (unit of analysis based on publicly available patent databases, 2023).

What is the competitive landscape?

Major players are generic drug manufacturers and a handful of innovator companies:

• PrimaThera, Mylan, and Sandoz produce generic versions.
• Limited innovation exists outside of formulation improvements and combination products.

Market share (by revenue):

• Top three generic manufacturers control approximately 70% of the market.
• Innovator companies hold niche positions due to limited new product development.

What are the future revenue projections?

Forecast (2023–2030):

• Market CAGR: approximately 4.3%.
• Market size expected to reach USD 1.7 billion by 2030.
• Expansion driven by increased demand in emerging markets and potential new indications.

Potential growth areas:

• Use in combination therapies targeting resistant bacterial strains.
• Development of sustained-release formulations.
• Expansion into veterinary medicine.

How do regional differences impact market potential?

Region	Market Share (%)	Growth Rate (2023–2030)	Key Factors
North America	35	3.8%	Regulatory complexity, high use of topical antibiotics
Europe	25	4.1%	Conservative regulation, growing wound care market
Asia-Pacific	25	6.2%	High population, expanding healthcare infrastructure
Latin America	10	5.0%	Rising healthcare access, urbanization

What are the key takeaways?

• The global market for bacitracin zinc and polymyxin B sulfate is growing modestly, with an emphasis on topical applications.
• Generic manufacturing dominates, applying downward pressure on prices.
• Regulatory differences influence regional market expansion.
• Growth projections indicate increasing demand, especially in emerging markets.
• Innovation primarily revolves around new formulations and combination products rather than novel active ingredients.

FAQs

1. How does antibiotic resistance affect the market for bacitracin zinc and polymyxin B sulfate? Resistance prompts both increased usage in resistant infections and regulatory scrutiny, influencing formulations and market growth.

2. Are new formulations likely to extend the market lifespan? Yes; sustained-release and combination products improve efficacy and compliance, supporting continued demand.

3. What role does regulation play in market access? Regulations determine prescription status, OTC availability, and reimbursement pathways, affecting sales volume and pricing.

4. Which geographies present the best growth opportunities? Asia-Pacific and Latin America offer the highest growth rates due to population size and evolving healthcare infrastructure.

5. What are the key risks to market stability? Regulatory restrictions, antibiotic resistance, and competitive pricing pressures from generics pose risks.

---

References

[1] Grand View Research. (2023). Topical Antibiotic Market Size, Share & Trends Analysis.
[2] U.S. Food and Drug Administration. (2023). Guidance for Industry: Topical Antibiotic Drug Products.
[3] MarketWatch. (2023). Global Antibiotics Market Size and Forecast.

Note: Data is based on market reports available as of 2023; actual figures may vary with future regulatory and technological developments.